Due to their immense oxygen needs, slow-twitch fibers are associated with many blood vessels, mitochondria, and increased concentrations of myoglobin, an oxygen-binding protein in the blood that provides muscles their reddish coloring.
Answer:
POINT MUTATION (SUBSTITUTION)
Explanation:
A point mutation is that mutation which involves only one nucleotide base. Point mutation can, however, occur in different ways such as SUBSTITUTION. Substitution point mutation is that which involves the replacement of a single nucleotide base by another in a gene sequence.
This is the case in this question regarding the mutation that causes sickle cell anaemia. According to this question, Sickle cell anemia is a disease that occurs when a mutation in the base pair of the hemoglobin beta gene causes a SINGLE replacement of GLUTAMIC ACID (Glu) by VALINE (Val). This shows that it is a type of SUBSTITUTION POINT MUTATION.
Answer:The answer Is Eubacteria
Explanation: I took the test ahaha :) Hope This helps.
Answer:
B
Explanation:
Amino acids fold to form the protein and give it its functionality. Different orders of amino acids fold differently and make a different shape. The shape of the protein defines its function. The function will vary wildly
Yes, it is true that Methylation of EZH2 by PRMT1 regulates its stability and promotes breast cancer metastasis.
Enhancer of zeste homolog 2 (EZH2), a key histone methyltransferase and EMT inducer, is overexpressed in diverse carcinomas, including breast cancer.
However, the molecular mechanisms of EZH2 dysregulation in cancers are still largely unknown. Here, we discover that EZH2 is asymmetrically dimethylated at R342 (meR342-EZH2) by PRMT1.
meR342-EZH2 was found to inhibit the CDK1-mediated phosphorylation of EZH2 at T345 and T487, thereby attenuating EZH2 ubiquitylation mediated by the E3 ligase TRAF6.
We also demonstrate that meR342-EZH2 resulted in a decrease in EZH2 target gene expression, but an increase in breast cancer cell EMT, invasion and metastasis.
Moreover, we confirm the positive correlations among PRMT1, meR342-EZH2 and EZH2 expression in the breast cancer tissues. Finally, we report that high expression levels of meR342-EZH2 predict a poor clinical outcome in breast cancer patients.
Our findings may provide a novel diagnostic target and promising therapeutic target for breast cancer metastasis.
Learn more about breast cancer here : brainly.com/question/6747562
#SPJ4
